In vitro transcribed messenger ribonucleic acid (mRNA) has emerged as a novel therapeutic platform. Lipid nanoparticles (LNPs) facilitate the effective delivery of mRNA to specific cell types and tissues, whilst enhancing stability. The efficacy, biodistribution, and potential toxicity of the therapeutic are determined in large part by the lipid composition of the LNP. Accordingly, the identity, quantity, and purity of the individual lipids are critical quality attributes of mRNA-LNP products.
Ultra-high performance liquid chromatography (UHPLC) coupled with Charged Aerosol Detection (CAD) is a powerful technique for the analysis of compounds, such as lipids, that do not contain chromophores. Explore results generated from an internal study using UHPLC-CAD and a proprietary mRNA-LNP formulation.